Home - Helix BioPharma
Helix BioPharma Corporation is a biopharmaceutical company mainly focused in the field of cancer therapy.
- Avoid using deprecated HTML tags.
Domain : www.helixbiopharma.com/
Character length : 23
Good! The OG (Open Graph) protocol is set on this website.
locale: en_US
type: website
title: Home - Helix BioPharma
description: New directions in cancer therapy Helix BioPharma Corporation is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. Helix is currently listed on TSX and FSE under the symbol “HBP” DOS47 Our most innovative technological platform for the treatment of solid tumors
url: http://www.helixbiopharma.com/
site_name: Helix BioPharma
image: http://mbmh.pl/development/helix/wp-content/uploads/2016/09/home_image.jpg
https://helixbiopharma.com/robots.txt
User-agent | Disallowed for the search engines |
---|---|
* |
|
No info found.
Character length : 22
Good! The title’s length is between 10 and 70 characters.
Error! The text / HTML code ratio is under 15 percent on this website. This value shows that the website has relatively few text content.
H1 | H2 | H3 | H4 | H5 | H6 |
---|---|---|---|---|---|
0 | 8 | 4 | 1 | 0 | 0 |
- <H3> New directions in cancer therapy
- <H2> DOS47
- <H4> Our most innovative technological platform for the treatment of solid tumors
- <H3> You can find us here:
- <H3> Helix is public listed company (HBP)
- <H3> Follow us
- <H2> News
- <H2> Helix Biopharma Corp. to Present CAR-T at AARC Annual Meeting 2017 in Washington, D.C.
- <H2> L-DOS47 Phase I Study Results to be Presented at the 9th International Conference of Contemporary Oncology
- <H2> Helix Biopharma Corp. Announces Ffiscal Second Quarter 2017 Results and Closing of Private Placement
- <H2> Helix Biopharma Corp. Announces Strategic Management Changes
- <H2> Helix Biopharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody from the Government of Canada
- <H2> 30mil CAD$ Investment in European Centre of Cancer Immunotherapy
- helix8
- biopharma6
- corp5
- cancer4
- announces3
- march3
- immunotherapy3
- presentation3
- conference3
- usa2
- home2
- platform2
- technological2
- february2
- annual2
- results2
- phase2
- poster2
- patients2
- listed2
- car-t2
- company2
- heman2
- therapies2
word | title | descriptions | heading |
---|---|---|---|
helix | |||
biopharma | |||
corp | |||
cancer | |||
announces | |||
march |
- helix biopharma5
- technological platform2
- cancer immunotherapy2
- for patients2
- helix biopharma corp4
Alternate attributes for the following 3 images are missing. Search engines use "alt" tags to understand image content efficiently. We strongly recommend fixing this issue.
- http://www.helixbiopharma.com/wp-content/themes/helix/js/plugins.js?ver=1.0
- http://www.helixbiopharma.com/wp-content/themes/helix/js/main.js?ver=1.0
- http://www.helixbiopharma.com/wp-content/plugins/contact-form-7/includes/js/jquery.form.min.js?ver=3.51.0-2014.06.20
- http://www.helixbiopharma.com/wp-content/plugins/contact-form-7/includes/js/scripts.js?ver=4.6
- http://www.helixbiopharma.com/wp-includes/js/wp-embed.min.js?ver=4.7.5
- http://www.helixbiopharma.com/wp-content/themes/helix/stylesheets/css/main.css?ver=1.0
- http://www.helixbiopharma.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=4.6
Internal links: 17
External links: 6